Review article: The role of molecular pathological epidemiology in the study of neoplastic and non-neoplastic diseases in the era of precision medicine

Epidemiology

Volumn 27, Issue 4, 2016, Pages 602-611

  Ogino, Shuji ^a,b,c   Nishihara, Reiko ^a,c   Vanderweele, Tyler J ^a   Wang, Molin ^a   Nishi, Akihiro ^d   Lochhead, Paul ^e,f   Qian, Zhi Rong ^c   Zhang, Xuehong ^c   Wu, Kana ^a   Nan, Hongmei ^g   Yoshida, Kazuki ^a,c   Milner, Danny A ^a,c   Chan, Andrew T ^c,f   Field, Alison E ^a,c,h   Camargo, Carlos A ^a,c,f   Williams, Michelle A ^a   Giovannucci, Edward L ^a,c  

^a HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

^c HARVARD MEDICAL SCHOOL   (United States)

^d YALE UNIVERSITY   (United States)

^e UNIVERSITY OF ABERDEEN   (United Kingdom)

^f MASSACHUSETTS GENERAL HOSPITAL   (United States)

^g INDIANA UNIVERSITY   (United States)

^h BOSTON CHILDREN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACUTE DISEASE; BIOINFORMATICS; BIOTECHNOLOGY; CARDIOVASCULAR DISEASE; CHRONIC DISEASE; DIABETES MELLITUS; DISEASE CLASSIFICATION; DISEASE SEVERITY; EDUCATION PROGRAM; GENETIC ASSOCIATION; HEALTH SCIENCE; HEREDITY; HUMAN; HYPOTHESIS; MOLECULAR DIAGNOSTICS; MOLECULAR EVOLUTION; MOLECULAR PATHOLOGICAL EPIDEMIOLOGY; MOLECULAR PATHOLOGY; NATIONAL HEALTH ORGANIZATION; NEOPLASM; OBESITY; PERSONALIZED MEDICINE; PRACTICE GUIDELINE; PRIORITY JOURNAL; PUBLIC HEALTH; REVIEW; SYSTEMS BIOLOGY; UNITED STATES; ADVERSE DRUG REACTION; COMMUNICABLE DISEASE; EPIGENETICS; GENE EXPRESSION PROFILING; GENETICS; GENOMICS; METABOLISM; METABOLOMICS; MICROFLORA; MOLECULAR EPIDEMIOLOGY; PROTEOMICS;

CARDIOVASCULAR DISEASES; COMMUNICABLE DISEASES; DIABETES MELLITUS; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; EPIGENOMICS; GENE EXPRESSION PROFILING; GENOMICS; HUMANS; METABOLOMICS; MICROBIOTA; MOLECULAR EPIDEMIOLOGY; NEOPLASMS; OBESITY; PATHOLOGY, MOLECULAR; PRECISION MEDICINE; PROTEOMICS;

EID: 84959307169     PISSN: 10443983     EISSN: 15315487     Source Type: Journal    
DOI: 10.1097/EDE.0000000000000471     Document Type: Review

References (100)

1. Ogino S, Fuchs CS, Giovannucci E. How many molecular subtypes? Implications of the unique tumor principle in personalized medicine. Expert Rev Mol Diagn. 2012;12:621-628.
2. Ogino S, Stampfer M. Lifestyle factors and microsatellite instability in colorectal cancer: the evolving field of molecular pathological epidemiology. J Natl Cancer Inst. 2010;102:365-367.
3. Ogino S, Chan AT, Fuchs CS, Giovannucci E. Molecular pathological epidemiology of colorectal neoplasia: an emerging transdisciplinary and interdisciplinary field. Gut. 2011;60:397-411.
4. Ogino S, Galon J, Fuchs CS, Dranoff G. Cancer immunology-Analysis of host and tumor factors for personalized medicine. Nat Rev Clin Oncol. 2011;8:711-719.
5. Kuller LH, Bracken MB, Ogino S, Prentice RL, Tracy RP. The role of epidemiology in the era of molecular epidemiology and genomics: summary of the 2013 AJE-sponsored Society of Epidemiologic Research Symposium. Am J Epidemiol. 2013;178:1350-1354.
6. Ogino S. Molecular pathological epidemiology (MPE): overview of its paradigm and wide applicability even without tumor tissue [abstract]. In: Proceedings of the Twelfth Annual AACR International Conference on Frontiers in Cancer Prevention Research; Oct 27-30, 2013; National Harbor, MD. Cancer Prev Res (Phila). 2013;6:CN06-01.
7. Epplein M, Bostick RM, Mu L, Ogino S, Braithwaite D, Kanetsky PA. Challenges and opportunities in international molecular cancer prevention research: an ASPO molecular epidemiology and the environment and international cancer prevention interest groups report. Cancer Epidemiol Biomarkers Prev. 2014;23:2613-2617.
8. Curtin K, Slattery ML, Samowitz WS. CpG island methylation in colorectal cancer: past, present and future. Patholog Res Int. 2011;2011:902674.
9. Hughes LA, Simons CC, van den Brandt PA, et al. Body size, physical activity and risk of colorectal cancer with or without the CpG island methylator phenotype (CIMP). PLoS One. 2011;6:e18571.
10. Jacobs RJ, Voorneveld PW, Kodach LL, Hardwick JC. Cholesterol metabolism and colorectal cancers. Curr Opin Pharmacol. 2012;12:690-695.
11. Hughes LA, Khalid-de Bakker CA, Smits KM, et al. The CpG island methylator phenotype in colorectal cancer: progress and problems. Biochim Biophys Acta. 2012;1825:77-85.
12. Iwagami S, Baba Y, Watanabe M, et al. Pyrosequencing assay to measure LINE-1 methylation level in esophageal squamous cell carcinoma. Ann Surg Oncol. 2012;19:2726-2732.
13. Limburg PJ, Limsui D, Vierkant RA, et al. Postmenopausal hormone therapy and colorectal cancer risk in relation to somatic KRAS mutation status among older women. Cancer Epidemiol Biomarkers Prev. 2012;21:681-684.
14. Hughes LA, Williamson EJ, van Engeland M, et al. Body size and risk for colorectal cancers showing BRAF mutations or microsatellite instability: a pooled analysis. Int J Epidemiol. 2012;41:1060-1072.
15. Ku CS, Cooper DN, Wu M, et al. Gene discovery in familial cancer syndromes by exome sequencing: prospects for the elucidation of familial colorectal cancer type X. Mod Pathol. 2012;25:1055-1068.
16. Rex DK, Ahnen DJ, Baron JA, et al. Serrated lesions of the colorectum: review and recommendations from an expert panel. Am J Gastroenterol. 2012;107:1315-29; quiz 1314, 1330.
17. Koshiol J, Lin SW. Can tissue-based immune markers be used for studying the natural history of cancer? Ann Epidemiol. 2012;22:520-530.
18. Fini L, Grizzi F, Laghi L. Adaptive and innate immunity, non clonal players in colorectal cancer progression. Edited by Ettarh R. InTech 2012 323-340.
19. Gay LJ, Mitrou PN, Keen J, et al. Dietary, lifestyle and clinicopathological factors associated with APC mutations and promoter methylation in colorectal cancers from the EPIC-Norfolk study. J Pathol. 2012;228: 405-415.
20. Galon J, Pages F, Marincola FM, et al. Cancer classification using the Immunoscore: a worldwide task force. J Transl Med. 2012;10:205.
21. Chia WK, Ali R, Toh HC. Aspirin as adjuvant therapy for colorectal cancer-reinterpreting paradigms. Nat Rev Clin Oncol. 2012;9:561-570.
22. Dogan S, Shen R, Ang DC, et al. Molecular epidemiology of EGFR and KRAS mutations in 3, 026 lung adenocarcinomas: higher susceptibility of women to smoking-related KRAS-mutant cancers. Clin Cancer Res. 2012;18:6169-6177.
23. Spitz MR, Caporaso NE, Sellers TA. Integrative cancer epidemiology-The next generation. Cancer Discov. 2012;2:1087-1090.
24. Shanmuganathan R, Basheer NB, Amirthalingam L, Muthukumar H, Kaliaperumal R, Shanmugam K. Conventional and nanotechniques for DNA methylation profiling. J Mol Diagn. 2013;15:17-26.
25. Rosty C, Young JP, Walsh MD, et al. Colorectal carcinomas with KRAS mutation are associated with distinctive morphological and molecular features. Mod Pathol. 2013;26:825-834.
26. Weijenberg MP, Hughes LA, Bours MJ, Simons CC, van Engeland M, van den Brandt PA. The mTOR pathway and the role of energy balance throughout life in colorectal cancer etiology and prognosis: unravelling mechanisms through a multidimensional molecular epidemiologic approach. Curr Nutr Rep. 2013;2:19-26.
27. Buchanan DD, Win AK, Walsh MD, et al. Family history of colorectal cancer in BRAF p.V600E-mutated colorectal cancer cases. Cancer Epidemiol Biomarkers Prev. 2013;22:917-926.
28. Burnett-Hartman AN, Newcomb PA, Potter JD, et al. Genomic aberrations occurring in subsets of serrated colorectal lesions but not conventional adenomas. Cancer Res. 2013;73:2863-2872.
29. Alvarez MC, Santos JC, Maniezzo N, et al. MGMT and MLH1 methylation in Helicobacter pylori-infected children and adults. World J Gastroenterol. 2013;19:3043-3051.
30. Hagland HR, Berg M, Jolma IW, Carlsen A, Soreide K. Molecular pathways and cellular metabolism in colorectal cancer. Dig Surg. 2013;30:12-25.
31. Zaidi N, Lupien L, Kuemmerle NB, Kinlaw WB, Swinnen JV, Smans K. Lipogenesis and lipolysis: the pathways exploited by the cancer cells to acquire fatty acids. Prog Lipid Res. 2013;52:585-589.
32. Abbenhardt C, Poole EM, Kulmacz RJ, et al.; Genetics and Epidemiology of Colorectal Cancer Consortium (GECCO) and CCFR. Phospholipase A2G1B polymorphisms and risk of colorectal neoplasia. Int J Mol Epidemiol Genet. 2013;4:140-149.
33. Hughes LA, Melotte V, de Schrijver J, et al. The CpG island methylator phenotype: what's in a name? Cancer Res. 2013;73:5858-5868.
34. Bae JM, Kim JH, Cho NY, Kim TY, Kang GH. Prognostic implication of the CpG island methylator phenotype in colorectal cancers depends on tumour location. Br J Cancer. 2013;109:1004-1012.
35. Amirian ES, Petrosino JF, Ajami NJ, Liu Y, Mims MP, Scheurer ME. Potential role of gastrointestinal microbiota composition in prostate cancer risk. Infect Agent Cancer. 2013;8:42.
36. Hoffmeister M, Blaker H, Kloor M, et al. Body mass index and microsatellite instability in colorectal cancer: a population-based study. Cancer Epidemiol Biomarkers Prev. 2013;22:2303-2311.
37. Araujo RF Jr, Lira GA, Guedes HG, et al. Lifestyle and family history influence cancer prognosis in Brazilian individuals. Pathol Res Pract. 2013;209:753-757.
38. Esterhuyse MM, Kaufmann SH. Diagnostic biomarkers are hidden in the infected host's epigenome. Expert Rev Mol Diagn. 2013;13:625-637.
39. Zhu Y, Yang SR, Wang PP, et al. Influence of pre-diagnostic cigarette smoking on colorectal cancer survival: overall and by tumour molecular phenotype. Br J Cancer. 2014;110:1359-1366.
40. Hagland HR, Soreide K. Cellular metabolism in colorectal carcinogenesis: Influence of lifestyle, gut microbiome and metabolic pathways. Cancer Lett. 2015;356(2 Pt A):273-280.
41. Shaheen NJ. What is behind the remarkable increase in esophageal adenocarcinoma? Am J Gastroenterol. 2014;109:345-347.
42. Brandstedt J, Wangefjord S, Nodin B, Eberhard J, Jirstrom K, Manjer J. Associations of hormone replacement therapy and oral contraceptives with risk of colorectal cancer defined by clinicopathological factors, betacatenin alterations, expression of cyclin D1, p53, and microsatellite-instability. BMC Cancer. 2014;14:371.
43. Coppede F. The role of epigenetics in colorectal cancer. Expert Rev Gastroenterol Hepatol. 2014;8:935-948.
44. Bishehsari F, Mahdavinia M, Vacca M, Malekzadeh R, Mariani-Costantini R. Epidemiological transition of colorectal cancer in developing countries: environmental factors, molecular pathways, and opportunities for prevention. World J Gastroenterol. 2014;20:6055-6072.
45. Cross AJ, Moore SC, Boca S, et al. A prospective study of serum metabolites and colorectal cancer risk. Cancer. 2014;120:3049-3057.
46. Simons CC, van den Brandt PA, Stehouwer CD, van Engeland M, Weijenberg MP. Body size, physical activity, early-life energy restriction, and associations with methylated insulin-like growth factor-binding protein genes in colorectal cancer. Cancer Epidemiol Biomarkers Prev. 2014;23:1852-1862.
47. Haque TR, Bradshaw PT, Crockett SD. Risk factors for serrated polyps of the colorectum. Dig Dis Sci. 2014;59:2874-2889.
48. Ryan BM, Wolff RK, Valeri N, et al. An analysis of genetic factors related to risk of inflammatory bowel disease and colon cancer. Cancer Epidemiol. 2014;38:583-590.
49. Huser V, Sincan M, Cimino JJ. Developing genomic knowledge bases and databases to support clinical management: current perspectives. Pharmgenomics Pers Med. 2014;7:275-283.
50. Wennersten C, Andersson G, Boman K, Nodin B, Gaber A, Jirstrom K. Incident urothelial cancer in the Malmo Diet and Cancer Study: cohort characteristics and further validation of ezrin as a prognostic biomarker. Diagn Pathol. 2014;9:189.
51. Mikeska T, Craig JM. DNA methylation biomarkers: cancer and beyond. Genes (Basel). 2014;5:821-864.
52. Campbell PT, Deka A, Briggs P, et al. Establishment of the cancer prevention study II nutrition cohort colorectal tissue repository. Cancer Epidemiol Biomarkers Prev. 2014;23:2694-2702.
53. Witvliet MI. World health survey: a useful yet underutilized global health data source. Austin J Public Health Epidemiol. 2014;1:id1012.
54. Li P, Wu H, Zhang H, et al. Aspirin use after diagnosis but not prediagnosis improves established colorectal cancer survival: a meta-Analysis. Gut. 2015;64:1419-1425.
55. Wild CP, Bucher JR, de Jong BW, et al. Translational cancer research: balancing prevention and treatment to combat cancer globally. J Natl Cancer Inst. 2015;107:353.
56. Caiazza F, Ryan EJ, Doherty G, Winter DC, Sheahan K. Estrogen receptors and their implications in colorectal carcinogenesis. Front Oncol. 2015;5:19.
57. Ng JM, Yu J. Promoter hypermethylation of tumour suppressor genes as potential biomarkers in colorectal cancer. Int J Mol Sci. 2015;16: 2472-2496.
58. Tillmans LS, Vierkant RA, Wang AH, et al. Associations between environmental exposures and incident colorectal cancer by ESR2 protein expression level in a population-based cohort of older women. Cancer Epidemiol Biomarkers Prev. 2015;24:713-719.
59. Cisyk AL, Penner-Goeke S, Lichtensztejn Z, et al. Characterizing the prevalence of chromosome instability in interval colorectal cancer. Neoplasia. 2015;17:306-316.
60. Weisenberger DJ, Levine AJ, Long TI, et al.; for the Colon Cancer Family Registry. Association of the colorectal CpG island methylator phenotype with molecular features, risk factors, and family history. Cancer Epidemiol Biomarkers Prev. 2015;24:512-519.
61. Gao C. Molecular pathological epidemiology: an interdisciplinary field for study of hepatocellular carcinoma. Austin J Gastroenterol. 2015;2:1040.
62. Szylberg L, Janiczek M, Popiel A, Marszalek A. Serrated polyps and their alternative pathway to the colorectal cancer: a systematic review. Gastroenterol Res Pract. 2015;2015:573814.
63. Wong EY, Chua C, Beh SY, Koh D, Chong D, Tan IB. Addressing the needs of colorectal cancer survivors: current strategies and future directions. Expert Rev Anticancer Ther. 2015;15:639-648.
64. Begg CB, Orlow I, Zabor EC, et al. Identifying etiologically distinct subtypes of cancer: a demonstration project involving breast cancer. Cancer Med. 2015;4:1432-1439.
65. Campbell PT, Newton CC, Newcomb PA, et al. Association between body mass index and mortality for colorectal cancer survivors: overall and by tumor molecular phenotype. Cancer Epidemiol Biomarkers Prev. 2015;24:1229-1238.
66. Mehta AM, Osse M, Kolkman-Uljee S, Fleuren GJ, Jordanova ES. Molecular backgrounds of ERAP1 downregulation in cervical carcinoma. Anal Cell Pathol (Amst). 2015;2015:367837.
67. Nishi A, Kawachi I, Koenen KC, Wu K, Nishihara R, Ogino S. Lifecourse epidemiology and molecular pathological epidemiology. Am J Prev Med. 2015;48:116-119.
68. Ogino S, Campbell PT, Nishihara R, et al. Proceedings of the second international molecular pathological epidemiology (MPE) meeting. Cancer Causes Control. 2015;26:959-972.
69. Ogino S, King EE, Beck AH, Sherman ME, Milner DA, Giovannucci E. Interdisciplinary education to integrate pathology and epidemiology: towards molecular and population-level health science. Am J Epidemiol. 2012;176:659-667.
70. Ogino S, Lochhead P, Chan AT, et al. Molecular pathological epidemiology of epigenetics: emerging integrative science to analyze environment, host, and disease. Mod Pathol. 2013;26:465-484.
71. Suzuki H, Yamamoto E, Maruyama R, Niinuma T, Kai M. Biological significance of the CpG island methylator phenotype. Biochem Biophys Res Commun. 2014;455:35-42.
72. Song M, Nishihara R, Wu K, et al. Marine omega-3 Polyunsaturated Fatty Acids and Risk of Colorectal Cancer According to Microsatellite Instability. J Natl Cancer Inst. 2015;107.
73. Lin JH, Giovannucci E. Environmental exposure and tumor heterogeneity in colorectal cancer risk and outcomes. Curr Colorectal Cancer Rep. 2014;10:94-104.
74. Nishihara R, Wu K, Lochhead P, et al. Long-Term colorectal-cancer incidence and mortality after lower endoscopy. N Engl J Med. 2013;369: 1095-1105.
75. Colussi D, Brandi G, Bazzoli F, Ricciardiello L. Molecular pathways involved in colorectal cancer: implications for disease behavior and prevention. Int J Mol Sci. 2013;14:16365-16385.
76. Febbo PG, Ladanyi M, Aldape KD, et al. NCCN task force report: evaluating the clinical utility of tumor markers in oncology. J Natl Compr Canc Netw. 2011;9(Suppl 5):S1-32; quiz S33.
77. Nosho K, Kure S, Irahara N, et al. A prospective cohort study shows unique epigenetic, genetic, and prognostic features of synchronous colorectal cancers. Gastroenterology. 2009;137:1609-20.e1.
78. Song M, Nishihara R, Wang M, et al. Plasma 25-hydroxyvitamin D and colorectal cancer risk according to tumour immunity status. Gut. 2016;65:296-304.
79. Chatterjee N, Sinha S, Diver WR, Feigelson HS. Analysis of cohort studies with multivariate and partially observed disease classification data. Biometrika. 2010;97:683-698.
80. Rosner B, Glynn RJ, Tamimi RM, et al. Breast cancer risk prediction with heterogeneous risk profiles according to breast cancer tumor markers. Am J Epidemiol. 2013;178:296-308.
81. Wang M, Kuchiba A, Ogino S. A meta-regression method for studying etiological heterogeneity across disease subtypes classified by multiple biomarkers. Am J Epidemiol. 2015;182:263-270.
82. Ogino S, Giovannucci E. Commentary: lifestyle factors and colorectal cancer microsatellite instability-molecular pathological epidemiology science, based on unique tumour principle. Int J Epidemiol. 2012;41:1072-1074.
83. Field AE, Camargo CA Jr, Ogino S. The merits of subtyping obesity: one size does not fit all. JAMA. 2013;310:2147-2148.
84. Yamauchi M, Morikawa T, Kuchiba A, et al. Assessment of colorectal cancer molecular features along bowel subsites challenges the conception of distinct dichotomy of proximal versus distal colorectum. Gut. 2012;61:847-854.
85. Yamauchi M, Lochhead P, Morikawa T, et al. Colorectal cancer: a tale of two sides or a continuum? Gut. 2012;61:794-797.
86. Mima K, Sukawa Y, Nishihara R, et al. Fusobacterium nucleatum and T cells in colorectal carcinoma. JAMA Oncol. 2015;1:653-661.
87. Ogino S, Lochhead P, Giovannucci E, Meyerhardt JA, Fuchs CS, Chan AT. Discovery of colorectal cancer PIK3CA mutation as potential predictive biomarker: power and promise of molecular pathological epidemiology. Oncogene. 2014;33:2949-2955.
88. Ikramuddin S, Livingston EH. New insights on bariatric surgery outcomes. JAMA. 2013;310:2401-2402.
89. van Winkel R. Aetiological stratification as a conceptual framework for gene-by-environment interaction research in psychiatry. Epidemiol Psychiatr Sci. 2015;24:6-11.
90. Ogino S, Goel A. Molecular classification and correlates in colorectal cancer. J Mol Diagn. 2008;10:13-27.
91. Lochhead P, Chan AT, Giovannucci E, et al. Progress and opportunities in molecular pathological epidemiology of colorectal premalignant lesions. Am J Gastroenterol. 2014;109:1205-1214.
92. Lochhead P, Chan AT, Nishihara R, et al. Etiologic field effect: reappraisal of the field effect concept in cancer predisposition and progression. Mod Pathol. 2015;28:14-29.
93. Liao X, Lochhead P, Nishihara R, et al. Aspirin use, tumor PIK3CA mutation, and colorectal-cancer survival. N Engl J Med. 2012;367: 1596-1606.
94. Domingo E, Church DN, Sieber O, et al. Evaluation of PIK3CA mutation as a predictor of benefit from nonsteroidal anti-inflammatory drug therapy in colorectal cancer. J Clin Oncol. 2013;31:4297-4305.
95. Fink SP, Yamauchi M, Nishihara R, et al. Aspirin and the risk of colorectal cancer in relation to the expression of 15-hydroxyprostaglandin dehydrogenase (HPGD). Sci Transl Med. 2014;6:233re2.
96. Chan AT, Ogino S, Fuchs CS. Aspirin and the risk of colorectal cancer in relation to the expression of COX-2. NEngl J Med. 2007;356:2131-2142.
97. Chan AT, Ogino S, Fuchs CS. Aspirin use and survival after diagnosis of colorectal cancer. JAMA. 2009;302:649-658.
98. Tougeron D, Sha D, Manthravadi S, Sinicrope FA. Aspirin and colorectal cancer: back to the future. Clin Cancer Res. 2014;20:1087-1094.
99. Ng K, Ogino S, Meyerhardt JA, et al. Relationship between statin use and colon cancer recurrence and survival: results from CALGB 89803. J Natl Cancer Inst. 2011;103:1540-1551.
100. Lee JE, Baba Y, Ng K, et al. Statin use and colorectal cancer risk according to molecular subtypes in two large prospective cohort studies. Cancer Prev Res (Phila). 2011;4:1808-1815.